At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 26 enrolled
Drug / intervention
Aurora A kinase inhibitor MLN8237 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II Study of Combination of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating Aurora A kinase inhibitor MLN8237 and bortezomib for Refractory Multiple Myeloma. Completed, enrolled 26 participants across 6 sites.
Detailed Summary
RATIONALE: Aurora A kinase inhibitor MLN8237 and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving aurora A kinase inhibitor MLN8237 together with bortezomib and to see how well they work in treating patients with relapsed or refractory multiple myeloma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Multiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 2009
Enrollment StartFeb 2010
Primary CompletionSep 2014
Study CompletionNov 2014
TodayJul 2026
First PostedDec 17, 2009
Enrollment StartFeb 1, 2010
Primary CompletionSep 1, 2014
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 16.5 years ago
Interventions
Aurora A kinase inhibitor MLN8237drug
Given orally
bortezomibdrug
Given IV